兔抗UBE2O多克隆抗體

Background:

E2/E3 hybrid ubiquitin-protein ligase that displays both E2 and E3 ligase activities and mediates monoubiquitination of target proteins (PubMed:23455153, PubMed:24703950). Negatively regulates TRAF6-mediated NF-kappa-B activation independently of its E2 activity (PubMed:23381138). Acts as a positive regulator of BMP7 signaling by mediating monoubiquitination of SMAD6, thereby regulating adipogenesis (PubMed:23455153). Mediates monoubiquitination at different sites of the nuclear localization signal (NLS) of BAP1, leading to cytoplasmic retention of BAP1. Also able to monoubiquitinate the NLS of other chromatin-associated proteins, such as INO80 and CXXC1, affecting their subcellular location (PubMed:24703950). Acts as a regulator of retrograde transport by assisting the TRIM27:MAGEL2 E3 ubiquitin ligase complex to mediate 'Lys-63'-linked ubiquitination of WASHC1, leading to promote endosomal F-actin assembly (PubMed:23452853).

Applications:

ELISA, IHC

Name of antibody:

UBE2O

Immunogen:

Fusion protein of human UBE2O

Full name:

ubiquitin conjugating enzyme E2 O

Synonyms:

E2-230K

SwissProt:

Q9C0C9

ELISA Recommended dilution:

5000-10000

IHC positive control:

Human thyroid cancer and Human gastric cancer

IHC Recommend dilution:

100-300